{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\nMiRNA-8074 acts as a regulatory molecule in multiple myeloma by modulating key genes such as TP53, MYC, MAPK1, and KIAA, all of which are central to the disease’s pathogenesis. The study demonstrated that elevated expression levels of miRNA-8074 correlate with adverse clinical parameters, suggesting that it may influence crucial oncogenic pathways in MM."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": ""}]}, {"type": "t", "text": "\n\n"}, {"type": "p", "children": [{"type": "t", "text": "\nFurthermore, high miRNA-8074 expression was significantly associated with reduced progression-free survival and overall survival in MM patients undergoing diverse treatment regimens, including thalidomide and bortezomib-based therapies. These findings highlight the potential value of miRNA-8074 not only as a molecule implicated in disease development but also as a prognostic biomarker that could improve risk stratification and guide treatment decisions in clinical settings."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": ""}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Aneta Szudy-Szczyrek, Radosław Mlak, Michał Mielnik, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Circulating Serum MiRNA-8074 as a Novel Prognostic Biomarker for Multiple Myeloma."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Cells (2022)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.3390/cells11040752"}], "href": "https://doi.org/10.3390/cells11040752"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "35203396"}], "href": "https://pubmed.ncbi.nlm.nih.gov/35203396"}]}]}]}